← All trials
NCT04424511
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2020
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 100000
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TampereLead sponsor
- Duke UniversityCollaborator
- University of LondonOverall official - principal investigator
- University of LondonCollaborator
- Bill and Melinda Gates FoundationCollaborator
- University of TampereReponsible party - principal investigator
- University of TampereOverall official - principal investigator
- Center for Vaccine Development CVD-MaliOverall official - principal investigator
- Center for Vaccine Development CVD-Mali, Bamako, MaliCollaborator
- Centre for Quantitative Medicine, Duke-NUS Medical SchoolOverall official - principal investigator
- Tro Da Ltd, UKOverall official - principal investigator
- Tro Da Ltd, UKCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.